Takeda’s Takhzyro Reduces HAE Attacks in Initial Phase of Treatment

Takeda Pharmaceutical has announced ad-hoc analysis data of a PIII study of its hereditary angioedema (HAE) treatment lanadelumab, known as Takhzyro overseas, suggesting that the drug starts to prevent HAE attacks during the early treatment phase. The study, called HELP,...read more